Pharmaceuticals & Life Sciences
PE-backed pharmaceutical manufacturers, distributors, and life sciences companies
PE-Owned Brands
Bausch & Lomb (KKR era)
Owned by KKR (Kohlberg Kravis Roberts)
KKR acquired Bausch Health's eye care business (Bausch + Lomb) in a partial stake deal as part of Bausch Health's debt restructuring. B+L IPO'd separately in 2022. KKR has extensive healthcare holdings including hospital operators, pharmaceutical companies, and physician groups.
Double Wood Supplements
Owned by Gryphon Investors
Direct-to-consumer dietary supplements brand. A current Gryphon Investors portfolio company.
GoodRx
Owned by Francisco Partners
Francisco Partners and Spectrum Equity created GoodRx, a prescription drug discount platform, and took it public in 2020 at a $18.7B valuation. GoodRx faced FTC action in 2023 for sharing users' sensitive prescription data with advertisers without proper consent.
Metagenics
Owned by Gryphon Investors
Practitioner-channel nutritional supplements maker. Gryphon Investors acquired Metagenics from Alticor in 2021.
PPD (Pharmaceutical Product Development)
Owned by The Carlyle Group
Carlyle Group and Hellman & Friedman acquired PPD, a global contract research organization, for $3.9B in 2011. PPD was acquired by Thermo Fisher Scientific for $21B in 2021. CROs like PPD have faced criticism for prioritizing speed over rigor in clinical trials.